{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:16:03Z","timestamp":1788988563192,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["MOP-82692"],"award-info":[{"award-number":["MOP-82692"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.neuropharm.2015.05.015","type":"journal-article","created":{"date-parts":[[2015,5,23]],"date-time":"2015-05-23T01:49:40Z","timestamp":1432345780000},"page":"86-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["The 5\u03b1-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease"],"prefix":"10.1016","volume":"97","author":[{"given":"Nadhir","family":"Litim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Bourque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Al Sweidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Morissette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2015.05.015_bib1","doi-asserted-by":"crossref","first-page":"e50040","DOI":"10.1371\/journal.pone.0050040","article-title":"Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease","volume":"7","author":"Adeosun","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib2","doi-asserted-by":"crossref","first-page":"14602","DOI":"10.1073\/pnas.0606544103","article-title":"Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis","volume":"103","author":"Ag\u00eds-Balboa","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0960-0760(97)00002-2","article-title":"Inhibition of rat \u03b1-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition","volume":"61","author":"Azzolina","year":"1997","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0091-3057(99)00168-9","article-title":"Gender differences in dopaminergic function in striatum and nucleus accumbens","volume":"64","author":"Becker","year":"1999","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrn1703","article-title":"Neurosteroids: endogenous regulators of the GABA(A) receptor","volume":"6","author":"Belelli","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib6","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1038\/npp.2008.39","article-title":"Antipsychotic-like properties of 5-alpha-reductase inhibitors","volume":"33","author":"Bortolato","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.yfrne.2009.04.014","article-title":"Neuroprotective actions of sex steroids in Parkinson's disease","volume":"30","author":"Bourque","year":"2009","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib8","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.neurobiolaging.2014.03.017","article-title":"Raloxifene activates G protein-coupled estrogen receptor 1\/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice","volume":"35","author":"Bourque","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib9","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1021\/ja953069t","article-title":"Mechanism-based inhibition of human steroid 5\u03b1-reductase by Finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor","volume":"118","author":"Bull","year":"1996","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","article-title":"Axon degeneration in Parkinson's disease","volume":"246","author":"Burke","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib11","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/cncr.24101","article-title":"Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype","volume":"115","author":"Calle","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/syn.1067","article-title":"Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl\/6 mice","volume":"41","author":"Callier","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib13","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/jc.2003-030330","article-title":"Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor","volume":"89","author":"Clark","year":"2004","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib14","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archneur.61.6.886","article-title":"Postmenopausal estrogen use affects risk for Parkinson disease","volume":"61","author":"Currie","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/syn.10145","article-title":"Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice","volume":"47","author":"D'Astous","year":"2003","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.yfrne.2013.03.001","article-title":"Neurosteroid and neurotransmitter alterations in Parkinson's disease","volume":"34","author":"di Michele","year":"2013","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1527-3458.2006.00053.x","article-title":"A\u00a0new look at the 5alpha-reductase inhibitor Finasteride","volume":"12","author":"Finn","year":"2006","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib18","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/brain\/awu107","article-title":"Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism","volume":"137","author":"Francardo","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib19","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Franklin","year":"2008"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.psyneuen.2012.07.014","article-title":"Inhibition of 5\u03b1-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL\/6 mice","volume":"38","author":"Frau","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2011.03.005","article-title":"Gene-environment interactions: key to unraveling the mystery of Parkinson's disease","volume":"94","author":"Gao","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib22","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.1073\/pnas.88.18.8044","article-title":"Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase","volume":"88","author":"George","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0169-328X(95)00278-Z","article-title":"Dopamine\u00a0transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease","volume":"36","author":"Harrington","year":"1996","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00023210-200418050-00001","article-title":"Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders","volume":"18","author":"Hayashi","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0014-2999(96)00252-X","article-title":"Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL\/6) and -insensitive (CD-1) mouse strains","volume":"307","author":"Kilbourn","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1023\/A:1007165307652","article-title":"Estrogen: a multifunctional messenger to nigrostriatal dopaminergic neurons","volume":"29","author":"K\u00fcppers","year":"2000","journal-title":"J. Neurocytol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jsbmb.2006.02.004","article-title":"Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women","volume":"99","author":"Labrie","year":"2006","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1592\/phco.19.11.951.31574","article-title":"Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men","volume":"19","author":"Lund","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib29","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1095\/biolreprod40.4.752","article-title":"Catecholamine effects on testicular testosterone production in the gonadally active and the gonadally regressed adult golden hamster","volume":"40","author":"Mayerhofer","year":"1989","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2013.09.005","article-title":"Allopregnanolone: state of the art","volume":"113","author":"Melcangi","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.1998.tb08230.x","article-title":"The impact of gender and estrogen on striatal dopaminergic neurotoxicity","volume":"844","author":"Miller","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mce.2008.04.008","article-title":"Estrogen and SERM neuroprotection in animal models of Parkinson's disease","volume":"290","author":"Morissette","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib33","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/npp.2011.142","article-title":"Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences","volume":"36","author":"Narboux-N\u00eame","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0960-0760(96)00083-0","article-title":"Metabolism of steroids in the brain: a new insight into the role of 5alpha-reductase and aromatase in brain differentiation and functions","volume":"58","author":"Negri-Cesi","year":"1996","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib35","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archneur.59.5.807","article-title":"Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity","volume":"59","author":"Okun","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/138161211795049589","article-title":"Steroid 5\u03b1-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders","volume":"17","author":"Paba","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1749-6632.2003.tb07476.x","article-title":"The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model","volume":"991","author":"Przedborski","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib38","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1212\/WNL.62.11.2010","article-title":"Risk of Parkinson disease in women: effect of reproductive characteristics","volume":"62","author":"Ragonese","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0015-0282(02)04389-3","article-title":"Role of environmental estrogens in the deterioration of male factor fertility","volume":"78","author":"Rozati","year":"2002","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.brainres.2008.06.116","article-title":"MPTP-induced Parkinsonism is associated with damage to Leydig cells and testosterone loss","volume":"1229","author":"Ruffoli","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev.bi.63.070194.000325","article-title":"Steroid 5 alpha-reductase: two genes\/two enzymes","volume":"63","author":"Russell","year":"1994","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib42","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1212\/WNL.52.7.1417","article-title":"The effect of estrogen replacement on early Parkinson's disease","volume":"52","author":"Saunders-Pullman","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib43","first-page":"283","article-title":"The impact of treatment with levodopa on Parkinson's disease","volume":"49","author":"Shaw","year":"1980","journal-title":"Q.\u00a0J. Med."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.expneurol.2014.03.010","article-title":"Sex differences in Parkinson's disease and other movement disorders","volume":"259","author":"Smith","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib45","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1021\/pr700686x","article-title":"A\u00a0connection between the mitochondrial permeability transition pore, autophagy, and cerebral amyloidogenesis","volume":"7","author":"Soski\u0107","year":"2008","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib46","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1286.007","article-title":"Neurosteroid biosynthesis in the human brain and its clinical implications","volume":"1007","author":"Stoffel-Wagner","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1126\/science.2832949","article-title":"Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems","volume":"240","author":"Su","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2015.05.015_bib48","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1016\/S0021-9258(18)42482-9","article-title":"Four-amino acid segment in steroid 5 alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor","volume":"267","author":"Thigpen","year":"1992","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0006-291X(03)01423-2","article-title":"Precise quantitation of 5\u03b1-reductase type 1 mRNA by RT-PCR in rat liver and its positive regulation by testosterone and dihydrotestosterone","volume":"308","author":"Torres","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbadis.2009.08.013","article-title":"Mitochondrial dysfunction in Parkinson's disease","volume":"1802","author":"Winklhofer","year":"2010","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"10.1016\/j.neuropharm.2015.05.015_bib51","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1158\/1078-0432.CCR-06-0184","article-title":"Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers","volume":"12","author":"Xu","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2015.05.015_bib52","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/S1353-8020(13)70032-4","article-title":"Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease","volume":"20","author":"Youdim","year":"2014","journal-title":"Parkinsonism Relat. Disord."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815001963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815001963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T04:31:45Z","timestamp":1683261105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390815001963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":52,"alternative-id":["S0028390815001963"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.05.015","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 5\u03b1-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}